Yasuhiro Oki
Overview
Explore the profile of Yasuhiro Oki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
164
Citations
4674
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hu B, Nastoupil L, Loghavi S, Westin J, Thakral B, Fayad L, et al.
Leuk Lymphoma
. 2019 Sep;
61(2):328-336.
PMID: 31533521
CD5+ diffuse large B-cell lymphoma (DLBCL), NOS represents a distinct subset of DLBCL associated with poorer outcomes and extranodal disease. We analyzed characteristics and outcomes for 102 CD5+ DLBCL patients...
12.
Strati P, Nastoupil L, Davis R, Fayad L, Fowler N, Hagemeister F, et al.
Haematologica
. 2019 May;
105(1):e26-e28.
PMID: 31073068
No abstract available.
13.
Barta S, Zain J, MacFarlane 4th A, Smith S, Ruan J, Fung H, et al.
Clin Lymphoma Myeloma Leuk
. 2019 Apr;
19(6):356-364.e3.
PMID: 31029646
Background: Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are frequently expressed in T-cell lymphomas. This provides a rationale for exploration of immune checkpoint inhibitors in the management of...
14.
Pinnix C, Dabaja B, Milgrom S, Smith G, Yehia Z, Nastoupil L, et al.
Head Neck
. 2019 Apr;
41(5):1546.
PMID: 30990235
No abstract available.
15.
Becnel M, Nastoupil L, Samaniego F, Davis R, You M, Green M, et al.
Br J Haematol
. 2019 Mar;
185(5):874-882.
PMID: 30919940
Lack of consensus for first-line marginal zone lymphoma (MZL) treatment and toxicities associated with currently available systemic therapies have inspired evaluation of immunotherapeutic agents yielding robust outcomes with improved tolerability....
16.
An Y, Jiang W, Andraos T, Reddy J, Yehia Z, Lloyd S, et al.
Radiother Oncol
. 2019 Feb;
131:88-92.
PMID: 30773193
Background And Purpose: A lower proportion of CD8+ tumor infiltrating lymphocytes in mycosis fungoides (MF) patients is associated with worse survival. However, it is not known whether circulating CD4:CD8 ratio...
17.
Milgrom S, Elhalawani H, Lee J, Wang Q, Mohamed A, Dabaja B, et al.
Sci Rep
. 2019 Feb;
9(1):1322.
PMID: 30718585
First-order radiomic features, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG), are associated with disease progression in early-stage classical Hodgkin lymphoma (HL). We hypothesized that a model...
18.
Chihara D, Oki Y, Fanale M, Westin J, Nastoupil L, Neelapu S, et al.
Ann Hematol
. 2019 Jan;
98(5):1169-1176.
PMID: 30617643
Stage I non-Hodgkin lymphoma (NHL) is rare; prognostic impact of different histologic subtypes and treatment modality is still unclear. We used the Surveillance, Epidemiology and End Results (SEER) database to...
19.
Chihara D, Oki Y
Cancer Treat Res
. 2019 Jan;
176:163-184.
PMID: 30596218
NK-cell malignancies are rare aggressive diseases associated with poor clinical outcome. There is a significant geographic variation in their incidence. At least a part of the reason for that is...
20.
Jensen G, Dabaja B, Pinnix C, Gunther J, Huen A, Duvic M, et al.
Case Rep Oncol
. 2018 Dec;
11(3):721-728.
PMID: 30519174
Background: Involvement of the central nervous system (CNS) by mycosis fungoides (MF) is rare; however, it portends a poor prognosis. While aggressive multimodality therapy may improve outcomes, the role of...